GLP-1s may not be suitable for people who: Have a history of pancreatitis Have certain thyroid conditions (e.g., medullary thyroid cancer) Are pregnant or breastfeeding (depending on the specific medication) Have severe gastrointestinal conditions, like gastroparesis GLP-1 receptor agonists, including Tirzepatide, have been shown to lead to significant weight loss, with many people losing 10-15% of their body weight over time
The Phase 1 high-dose trial explored doses up to 16 mg, finding that the compound remained well tolerated even at these higher levels
Diabetes 67 , 522P (2018) A.B
GLP-1 receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying in research models GIP receptor activation potentiates insulin secretion and modulates adipose tissue metabolism in preclinical studies Glucagon receptor partial agonism supports hepatic glucose output modulation and increased energy expenditure at physiological concentrations in research models The simultaneous engagement of all three receptors produces coordinated effects on insulin secretion, glucagon suppression, energy expenditure, and metabolic signaling studied in preclinical models and referenced in peer-reviewed literature
, ,
